Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PEPD | P12955 | 2/20 | 0.41 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13910188 | 1.00 | TSHR (0.46) | TSHRPOLBPEPDXPNPEP1FKBP1A | |
| SCHEMBL1684095 | 1.00 | TSHR (0.46) | TSHRPOLBPEPDXPNPEP1FKBP1A | |
| SCHEMBL12205469 | 0.95 | FKBP1A (0.46) | TSHRPOLBPEPDXPNPEP1FKBP1A | |
| SCHEMBL12572934 | 0.95 | FKBP1A (0.46) | TSHRPOLBPEPDXPNPEP1FKBP1A | |
| SCHEMBL27476799 | 0.89 | TSHR (0.49) | TSHRPOLBPEPDXPNPEP1FKBP1A | |
| SCHEMBL2768929 | 0.89 | TP53 (0.38) | TSHRPOLBPEPDXPNPEP1FKBP1A | |
| SCHEMBL10368163 | 0.87 | TSHR (0.45) | TSHRPOLBPEPDXPNPEP1FKBP1A | |
| SCHEMBL26999873 | 0.86 | TSHR (0.44) | TSHRPOLBPEPDXPNPEP1FKBP1A | |
| SCHEMBL24283107 | 0.84 | RAB9A (0.36) | TSHRPOLBPEPDRAB9A | |
| SCHEMBL20053224 | 0.84 | CTSL (0.40) | TSHRPOLBPEPDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502384-B2 | Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230190732-A1 | PHARMACEUTICAL COMPOSITION CONTAINING NITROXOLINE PRODRUG, AND PREPARATION METHOD AND APPLICATION THEREFOR | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2020-06-11 | — | — | US | disclosed |
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10307434-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-06-04 | — | — | US | disclosed |
| US-20190161499-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| WO-2019076310-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-04-25 | — | — | WO | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-20070270407-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-7247648-B2 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | EGFR, ERBB2, ERBB3 | TSHR 1275/4885POLB 3343/4885PEPD 3891/4885 |
| US-20190161499-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | ACHE, AADAC, ATL3 | TSHR 2070/4885POLB 4561/4885PEPD 59/4885 |
| US-20200181090-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | TSHR 4175/4885POLB 1866/4885PEPD 4302/4885 |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, CYP51A1, CD4 | TSHR 4120/4885POLB 429/4885PEPD 1581/4885 |
| US-20080167340-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | TSHR 4175/4885POLB 1866/4885PEPD 4302/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | TSHR 2897/4885POLB 4819/4885PEPD 3786/4885 |
| US-20070270407-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, IFNG, CD4 | TSHR 3812/4885POLB 406/4885PEPD 1203/4885 |
| US-10472327-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | TSHR 4175/4885POLB 1866/4885PEPD 4302/4885 |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | TSHR 4175/4885POLB 1866/4885PEPD 4302/4885 |
| US-12502384-B2 | Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor | PDE7A, CYP4X1, UGT1A7 | TSHR 4420/4885POLB 1432/4885PEPD 2079/4885 |
| US-20230190732-A1 | PHARMACEUTICAL COMPOSITION CONTAINING NITROXOLINE PRODRUG, AND PREPARATION METHOD AND APPLICATION THEREFOR | PDE7A, CYP4X1, UGT1A7 | TSHR 4420/4885POLB 1432/4885PEPD 2079/4885 |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | KRAS, NRAS, HRAS | TSHR 4220/4885POLB 845/4885PEPD 1917/4885 |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | COQ8A, MAP3K7, PRKG2 | TSHR 4377/4885POLB 1544/4885PEPD 3146/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | TSHR 4766/4885POLB 582/4885PEPD 2841/4885 |
| US-10307434-B2 | Nucleic acid prodrugs and methods of use thereof | PNP, RNGTT, NSUN2 | TSHR 3338/4885POLB 39/4885PEPD 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.